Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
RESEARCH TOOLSreports
Arvinas Holding Company (ARVN) Stock Price & Analysis
785 Followers
ARVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.57 - $53.08
Previous Close$35.23
Volume480.98K
Average Volume (3M)727.05K
Market Cap
$2.41B
Enterprise Value$1.15B
Total Cash (Recent Filing)$1.26B
Total Debt (Recent Filing)$3.20M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 06, 2024EPS Estimate
-$1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.93
Shares Outstanding68,431,891
10 Day Avg. Volume782,855
30 Day Avg. Volume727,054
Standard Deviation0.39
R-Squared0.07
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.65
Price to Sales (P/S)30.71
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.69
Enterprise Value/Gross Profit14.69
Enterprise Value/Ebitda-3.07
Forecast
1Y Price Target
$65.33Price Target Upside85.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Arvinas Holding Company News
PremiumCompany Announcements
Arvinas and Pfizer Breast Cancer Trial Shows Promising ResultsBulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination of vepdegestrant and palbociclib has demonstrated competitive efficacy and a high Clinical Benefit Rate, positioning it favorably against alternative treatments.
Drug DevelopmentThe progression to a Phase 3 trial for vepdegestrant reflects the company's confidence in the drug's potential, signaling a strong commitment to its successful development and future commercialization.
Financial OutlookAnalyst maintains a Buy rating and a $70 price target for the stock, underpinned by a robust financial analysis and positive clinical trial results, suggesting a promising outlook for the company's performance.
Bears Say
Clinical Trial ResultsWhile CBR (~85%) was numerically higher than vepdegestrant + palbo combo (~63%), the data does not look differentiated versus ARVN's at this time.
Financial PerformancePrice Target decreased due to dilution following a private placement.
Stock PerformanceShares have experienced a significant pullback, reflecting investor concerns about execution risks and competitive pressures, which may impact stock performance.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $13.57 and its highest was $53.08 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Currently, no data Available
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Aug 06, 2024 which is in 73 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on May 07, 2024. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.42 by $0.45.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -$1.12.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 68,431,890 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.42. Following the earnings report the stock price went up 6.417%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Among the largest hedge funds holding Arvinas Holding Company’s share is New Leaf Venture Partners, L.L.C.. It holds Arvinas Holding Company’s shares valued at 53M.
---
Arvinas Holding Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.33 (85.44% Upside)
$65.33 (85.44% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 924.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $484.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.79%
12-Months-Change
Fundamentals
Return on Equity
-63.32%
Trailing 12-Months
Asset Growth
3.13%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
---
ARVN Stock 12 Month Forecast
Average Price Target
$65.33
▲(85.44% Upside)
Technical Analysis
Best Analysts Covering ARVN
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+29.42%
initiated a buy rating 18 days ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +29.42% per trade.
---